☰

Lindsey D. Mayo - Publications

Affiliations: 
Biochemistry and Molecular Biology Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Molecular Biology, Biochemistry, General Biology
Tree Info Grants Similar researchers PubMed Report error

72 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Chen S, Wang Q, Yu H, Capitano ML, Vemula S, Nabinger SC, Gao R, Yao C, Kobayashi M, Geng Z, Fahey A, Henley D, Liu SZ, Barajas S, Cai W, ... ... Mayo LD, et al. Author Correction: Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nature Communications. 11: 3856. PMID 32724180 DOI: 10.1038/S41467-020-17555-0  0.369
2020 Wolf ER, Mabry AR, Damania B, Mayo LD. Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors. Oncogene. PMID 32555333 DOI: 10.1038/S41388-020-1359-4  0.532
2019 Chen S, Wang Q, Yu H, Capitano ML, Vemula S, Nabinger SC, Gao R, Yao C, Kobayashi M, Geng Z, Fahey A, Henley D, Liu SZ, Barajas S, Cai W, ... ... Mayo LD, et al. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nature Communications. 10: 5649. PMID 31827082 DOI: 10.1038/S41467-019-13542-2  0.45
2019 Nabinger SC, Chen S, Gao R, Yao C, Kobayashi M, Vemula S, Fahey AC, Wang C, Daniels C, Boswell HS, Sandusky GE, Mayo LD, Kapur R, Liu Y. Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development. Leukemia. PMID 30675010 DOI: 10.1038/S41375-019-0377-0  0.398
2018 Wang J, Shen T, Zhu W, Dou L, Gu H, Zhang L, Yang Z, Chen H, Zhou Q, Sanchez ER, Field L, Mayo LD, Xie Z, Xiao D, Lin X, et al. Protein phosphatase 5 and the tumor suppressor P53 down-regulate each other's activities in mice. The Journal of Biological Chemistry. PMID 30262665 DOI: 10.1074/Jbc.Ra118.004256  0.574
2018 Olivos DJ, Perrien DS, Hooker A, Cheng YH, Fuchs RK, Hong JM, Bruzzaniti A, Chun K, Eischen CM, Kacena MA, Mayo LD. The proto-oncogene function of Mdm2 in bone. Journal of Cellular Biochemistry. PMID 30011084 DOI: 10.1002/Jcb.27133  0.308
2018 Wolf ER, McAtarsney CP, Bredhold KE, Kline AM, Mayo LD. Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK. Science Signaling. 11. PMID 29615516 DOI: 10.1126/Scisignal.Aao4170  0.553
2017 Chen S, Gao R, Yao C, Kobayashi M, Liu SZ, Yoder MC, Broxmeyer H, Kapur R, Boswell HS, Mayo LD, Liu Y. Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53. Leukemia. PMID 29263439 DOI: 10.1038/Leu.2017.325  0.373
2017 Hauck PM, Wolf ER, Olivos DJ, McAtarsney CP, Mayo LD. The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2). Oncotarget. 8: 104455-104466. PMID 29262653 DOI: 10.18632/Oncotarget.22320  0.55
2017 Hauck P, Wolf E, Olivos D, Batuello CN, McElyea K, McAtarsney C, Cournoyer M, Sandusky GE, Mayo LD. Early Stage Metastasis require Mdm2 and not p53 Gain of Function. Molecular Cancer Research : McR. PMID 28784612 DOI: 10.1158/1541-7786.Mcr-17-0174  0.762
2017 Olivos DJ, Chtcherbinine M, Wolf ER, McAtarsney C, Mayo LD. Abstract 2552: MDM2 induces cell fusion in breast cancer and osteosarcoma Cancer Research. 77: 2552-2552. DOI: 10.1158/1538-7445.Am2017-2552  0.34
2016 Olivos DJ, Mayo LD. Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. International Journal of Molecular Sciences. 17. PMID 27898034 DOI: 10.3390/Ijms17121982  0.464
2016 Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, ... ... Mayo LD, et al. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist. Journal of Neurosurgery. 1-14. PMID 27177180 DOI: 10.3171/2016.1.Jns152513  0.521
2016 Olivos DJ, Mayo LD. Abstract 5109: MDM2 regulates intracellular pathways in TNBC and osteosarcoma that affect osteoclastogenesis Cancer Research. 76: 5109-5109. DOI: 10.1158/1538-7445.Am2016-5109  0.427
2016 Hauck PM, Mayo LD. Abstract 3702: Src phosphorylated Mdm2 requires MdmX to act as a neddylating ligase Cancer Research. 76: 3702-3702. DOI: 10.1158/1538-7445.Am2016-3702  0.522
2015 Tonsing-Carter E, Bailey BJ, Saadatzadeh MR, Ding J, Wang H, Sinn AL, Peterman KM, Spragins TK, Silver JM, Sprouse AA, Georgiadis TM, Gunter TZ, Long EC, Minto RE, Marchal CC, ... ... Mayo LD, et al. Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model. Molecular Cancer Therapeutics. PMID 26494859 DOI: 10.1158/1535-7163.Mct-15-0237  0.767
2015 Batuello CN, Hauck PM, Gendron JM, Lehman JA, Mayo LD. Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligase. Proceedings of the National Academy of Sciences of the United States of America. 112: 1749-54. PMID 25624478 DOI: 10.1073/Pnas.1416656112  0.801
2015 Cheng YH, Streicher DA, Waning DL, Chitteti BR, Gerard-O'Riley R, Horowitz MC, Bidwell JP, Pavalko FM, Srour EF, Mayo LD, Kacena MA. Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells. Journal of Cellular Physiology. 230: 578-86. PMID 25160801 DOI: 10.1002/Jcp.24774  0.434
2015 Olivos DJ, Mayo LD. Abstract 2241: MDM2 silencing promotes tumor-initiating cells in osteosarcoma and breast cancer Cancer Research. 75: 2241-2241. DOI: 10.1158/1538-7445.Am2015-2241  0.376
2014 Lakhter AJ, Hamilton J, Dagher PC, Mukkamala S, Hato T, Dong XC, Mayo LD, Harris RA, Shekhar A, Ivan M, Brustovetsky N, Naidu SR. Ferroxitosis: a cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma. Oncotarget. 5: 12694-703. PMID 25587028 DOI: 10.18632/Oncotarget.3031  0.334
2014 Wang H, Cai S, Bailey BJ, Gelbert LM, Saadatzadeh MR, Cohen-Gadol AA, Sarkaria JN, Territo P, Georgiadis TM, Gunter TZ, Meroueh S, Long EC, Jones DR, Mayo LD, Harlan S, et al. Abstract 2741: Sensitization of temozolomide-mediated glioblastoma cell death by targeting MDM2: Assessment of PD biomarkers, brain penetration, and efficacy in humanized orthotopic xenograft models Cancer Research. 74: 2741-2741. DOI: 10.1158/1538-7445.Am2014-2741  0.458
2014 Tonsing-Carter E, Shannon HE, Bailey BJ, Sinn AL, Peterman KM, Mayo LD, Pollok KE. Abstract 1680: Modulation of MDM2 in context of DNA damage enhances cell death in a metastatic breast-to-lung xenograft model Cancer Research. 74: 1680-1680. DOI: 10.1158/1538-7445.Am2014-1680  0.456
2013 Lehman JA, Hauck PM, Gendron JM, Batuello CN, Eitel JA, Albig A, Kadakia MP, Mayo LD. Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. Plos One. 8: e74741. PMID 24040331 DOI: 10.1371/Journal.Pone.0074741  0.782
2013 Wang H, Cai S, Ernstberger A, Bailey BJ, Wang MZ, Cai W, Goebel WS, Czader MB, Crean C, Suvannasankha A, Shokolenkoc I, Wilson GL, Baluyut AR, Mayo LD, Pollok KE. Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2699-709. PMID 23536437 DOI: 10.1158/1078-0432.Ccr-12-2671  0.375
2013 Cheng YH, Hooker RA, Nguyen K, Gerard-O'Riley R, Waning DL, Chitteti BR, Meijome TE, Chua HL, Plett AP, Orschell CM, Srour EF, Mayo LD, Pavalko FM, Bruzzaniti A, Kacena MA. Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 1434-45. PMID 23362087 DOI: 10.1002/Jbmr.1876  0.341
2013 Jackson JL, Grothaus KA, Temm CJ, Mayo LD, Sanduksy GE. Abstract 5380: Detection of OvCa1 in human malignancies. Cancer Research. 73: 5380-5380. DOI: 10.1158/1538-7445.Am2013-5380  0.357
2013 Tonsing-Carter E, Shannon HE, Bailey BJ, Mayo LD, Pollok KE. Abstract 4639: Blockade of MDM2-mediated signaling in context of DNA damage increases E2F1 expression and enhances cell death in triple-negative breast cancer cells. Cancer Research. 73: 4639-4639. DOI: 10.1158/1538-7445.Am2013-4639  0.477
2013 Shannon HE, Wang H, Cai S, Liu WM, Gelbert LM, Cohen-Gadol AA, Sarkaria JN, Mayo LD, Pollok KE. Abstract 3435: MDM2 as a therapeutic target: improving upon front-line chemotherapy for nervous system tumors. Cancer Research. 73: 3435-3435. DOI: 10.1158/1538-7445.Am2013-3435  0.549
2012 Lehman JA, Mayo LD. Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis. International Journal of Molecular Sciences. 13: 16373-86. PMID 23208375 DOI: 10.3390/Ijms131216373  0.457
2012 Mayo LD. Directing p53 to induce autophagy. Cell Cycle (Georgetown, Tex.). 11: 3353-4. PMID 22918242 DOI: 10.4161/Cc.21849  0.348
2012 Zhang Y, Zhang Q, Zeng SX, Zhang Y, Mayo LD, Lu H. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biology & Therapy. 13: 915-24. PMID 22785205 DOI: 10.4161/Cbt.20844  0.559
2012 Kacena MA, Eleniste PP, Cheng YH, Huang S, Shivanna M, Meijome TE, Mayo LD, Bruzzaniti A. Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts. The Journal of Biological Chemistry. 287: 17257-68. PMID 22447931 DOI: 10.1074/Jbc.M111.309880  0.378
2012 Wang H, Cai S, Cai W, Ernstberger AG, Wang MZ, Shokolenko I, Wilson G, Goebel WS, Baluyut AR, Mayo LD, Pollok KE. Abstract 4671: Assessment of molecular processes relative to DNA damage response using primary human hematopoietic cells exposed to high-dose chemotherapy Cancer Research. 72: 4671-4671. DOI: 10.1158/1538-7445.Am2012-4671  0.432
2011 Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, Mayo LD. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress. The Journal of Biological Chemistry. 286: 36631-40. PMID 21873427 DOI: 10.1074/Jbc.M110.217620  0.8
2011 Leonard MK, Kommagani R, Payal V, Mayo LD, Shamma HN, Kadakia MP. ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization. Cell Death and Differentiation. 18: 1924-33. PMID 21637289 DOI: 10.1038/Cdd.2011.73  0.488
2011 Goetz EM, Shankar B, Zou Y, Morales JC, Luo X, Araki S, Bachoo R, Mayo LD, Boothman DA. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability. Oncogene. 30: 3745-54. PMID 21460853 DOI: 10.1038/Onc.2011.92  0.454
2011 Waning DL, Lehman JA, Batuello CN, Mayo LD. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation. The Journal of Biological Chemistry. 286: 216-22. PMID 21081495 DOI: 10.1074/Jbc.M110.183012  0.776
2011 Cai S, Wang H, Bailey B, Ernstberger A, Juliar BE, Sinn AL, Chan RJ, Jones DR, Mayo LD, Baluyut AR, Goebel WS, Pollok KE. Abstract 2543: Humanized bone-marrow mouse model as a pre-clinical tool to assess therapy-mediated hematotoxicity Cancer Research. 71: 2543-2543. DOI: 10.1158/1538-7445.Am2011-2543  0.306
2010 Waning DL, Lehman JA, Batuello CN, Mayo LD. Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel, Switzerland). 3: 1576-1593. PMID 20651945 DOI: 10.3390/Ph3051576  0.803
2010 Cipriano R, Patton JT, Mayo LD, Jackson MW. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis. Cell Cycle (Georgetown, Tex.). 9: 1373-9. PMID 20305378 DOI: 10.4161/Cc.9.7.11193  0.516
2010 Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA, Mayo LD. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. The Journal of Clinical Investigation. 120: 290-302. PMID 19955655 DOI: 10.1172/Jci39194  0.75
2010 Wang H, Cai S, Bailey BJ, Sinn AL, Silver JM, Minto RE, Georgiadis TM, Long EC, Sarkaria JN, Mayo LD, Pollok KE. Abstract 5373: Modulation of temozolomide-mediated DNA damage in glioblastoma multiforme by the HDM2 antagonist, nutlin3 Cancer Research. 70: 5373-5373. DOI: 10.1158/1538-7445.Am10-5373  0.487
2010 Waning DL, Mayo LD. Abstract 5069: c-Abl contributes to Mdm2-Mdmx complex formation protecting p53 levels Cancer Research. 70: 5069-5069. DOI: 10.1158/1538-7445.Am10-5069  0.563
2009 Yadavilli S, Mayo LD, Higgins M, Lain S, Hegde V, Deutsch WA. Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. Dna Repair. 8: 1215-24. PMID 19656744 DOI: 10.1016/J.Dnarep.2009.07.003  0.497
2009 Gama V, Gomez JA, Mayo LD, Jackson MW, Danielpour D, Song K, Haas AL, Laughlin MJ, Matsuyama S. Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization. Cell Death and Differentiation. 16: 758-69. PMID 19247369 DOI: 10.1038/Cdd.2009.6  0.446
2009 Eitel JA, Bijangi-Vishehsaraei K, Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE, Mayo LD. PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle (Georgetown, Tex.). 8: 896-901. PMID 19221500 DOI: 10.4161/Cc.8.6.7899  0.548
2008 Lehman JA, Eitel JA, Batuello CN, Mayo LD. Therapeutic considerations for Mdm2: not just a one trick pony. Expert Opinion On Drug Discovery. 3: 1309-1321. PMID 19738896 DOI: 10.1517/17460441.3.11.1309  0.791
2007 LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Research. 67: 450-4. PMID 17234751 DOI: 10.1158/0008-5472.Can-06-2710  0.442
2007 Gama V, Gomez JA, Mayo LD, Haas AL, Matsuyama S. Hdm2 Is an Ubiquitin Ligase for the Anti-Apoptotic Protein Ku70. Blood. 110: 3347-3347. DOI: 10.1182/Blood.V110.11.3347.3347  0.542
2006 Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. The Journal of Biological Chemistry. 281: 16814-20. PMID 16621805 DOI: 10.1074/Jbc.M511617200  0.487
2006 Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Research. 66: 3169-76. PMID 16540668 DOI: 10.1158/0008-5472.Can-05-3832  0.535
2006 Schmidt NW, Mayo LD, Donner DB, Kaplan MH. p53 regulates Btk-dependent B cell proliferation but not differentiation. Journal of Leukocyte Biology. 79: 852-9. PMID 16461747 DOI: 10.1189/Jlb.0705402  0.387
2006 Gama V, Yoshida T, Gomez JA, Basile DP, Mayo LD, Haas AL, Matsuyama S. Involvement of the ubiquitin pathway in decreasing Ku70 levels in response to drug-induced apoptosis. Experimental Cell Research. 312: 488-99. PMID 16368436 DOI: 10.1016/J.Yexcr.2005.11.016  0.422
2005 Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. The Journal of Biological Chemistry. 280: 25953-9. PMID 15843377 DOI: 10.1074/Jbc.M503026200  0.572
2005 Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, Boothman DA. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. The Journal of Biological Chemistry. 280: 14212-21. PMID 15689620 DOI: 10.1074/Jbc.M412569200  0.354
2005 Araki S, Israel S, Leskov KS, Criswell TL, Beman M, Klokov DY, Sampalth L, Reinicke KE, Cataldo E, Mayo LD, Boothman DA. Clusterin proteins: stress-inducible polypeptides with proposed functions in multiple organ dysfunction British Journal of Radiology. 106-113. DOI: 10.1259/Bjr/18105113  0.305
2004 Klokov D, Criswell T, Leskov KS, Araki S, Mayo L, Boothman DA. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutation Research. 568: 97-110. PMID 15530543 DOI: 10.1016/J.Mrfmmm.2004.06.049  0.387
2004 Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR, Korgaonkar CK, Donner DB. Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells. American Journal of Physiology. Cell Physiology. 286: C547-55. PMID 14761884 DOI: 10.1152/Ajpcell.00332.2002  0.484
2004 Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. The Journal of Biological Chemistry. 279: 1615-20. PMID 14585846 DOI: 10.1074/Jbc.M306976200  0.385
2003 Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Research. 63: 3585-92. PMID 12839945  0.405
2002 Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends in Biochemical Sciences. 27: 462-7. PMID 12217521 DOI: 10.1016/S0968-0004(02)02166-7  0.539
2002 Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. The Journal of Biological Chemistry. 277: 5484-9. PMID 11729185 DOI: 10.1074/Jbc.M108302200  0.609
2001 Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences of the United States of America. 98: 11598-603. PMID 11504915 DOI: 10.1073/Pnas.181181198  0.521
2001 Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB. Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase. The Journal of Biological Chemistry. 276: 25184-9. PMID 11335727 DOI: 10.1074/Jbc.M102932200  0.428
2001 Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proceedings of the National Academy of Sciences of the United States of America. 98: 4640-5. PMID 11287630 DOI: 10.1073/Pnas.051042298  0.331
2000 Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. The Journal of Biological Chemistry. 275: 11216-21. PMID 10753929 DOI: 10.1074/Jbc.275.15.11216  0.401
2000 Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB. VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. The Journal of Biological Chemistry. 275: 6059-62. PMID 10692392 DOI: 10.1074/Jbc.275.9.6059  0.345
2000 Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. The Journal of Biological Chemistry. 275: 5096-103. PMID 10671553 DOI: 10.1074/Jbc.275.7.5096  0.386
1999 Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401: 82-5. PMID 10485710 DOI: 10.1038/43466  0.329
1999 Berberich SJ, Litteral V, Mayo LD, Tabesh D, Morris D. mdm-2 gene amplification in 3T3-L1 preadipocytes. Differentiation; Research in Biological Diversity. 64: 205-12. PMID 10365438 DOI: 10.1046/J.1432-0436.1999.6440205.X  0.406
1997 Mayo LD, Turchi JJ, Berberich SJ. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Research. 57: 5013-6. PMID 9371494  0.457
1996 Mayo LD, Berberich SJ. Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation. Oncogene. 13: 2315-21. PMID 8957072  0.354
Show low-probability matches.